2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow 4SC-201: new trials by email Literature Review of 4SC-201 trials Research Report on 4SC-201
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Resminostat for Maintenance Treatment of Patients With Advanced Stage Mycosis Fungoides (MF) or Sézary Syndrome (SS) resminostat, Placebo - Mycosis Fungoides, Sezary Syndrome | Phase 2 | Completed | 4SC AG | 201 | 2016-11-01 | 2024-08-30 |
| 4SC-201 (Resminostat) and Sorafenib in Advanced Hepatocellular Carcinoma 4SC-201, Sorafenib - Hepatocellular Carcinoma | Phase 2 | Completed | 4SC AG | 57 | 2009-07-01 | 2014-01-16 |
Carcinoma, Hepatocellular (1) · Lymphoma, T-Cell, Cutaneous (1) · Mycosis Fungoides (1) · Sezary Syndrome (1)
4SC AG (2)
Germany (2) · Italy (2) · Austria (1) · Belgium (1) · France (1) · Greece (1) · Japan (1) · Netherlands (1) · Poland (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Michael Bitzer, Prof. MD (1) · Rudolf Stadler, Prof. (1)
PMID 26952006, PMID 32632956, PMID 41651641
2016 (1)